优化治疗类风湿关节炎的低剂量甲氨蝶呤：综述。
Optimising low-dose methotrexate for rheumatoid arthritis-A review.
机构信息
Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
出版信息
Br J Clin Pharmacol. 2019 Oct;85(10):2228-2234. doi: 10.1111/bcp.14057. Epub 2019 Aug 9.
Abstract
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
摘要
甲氨蝶呤低剂量（5-25 毫克/周）是类风湿关节炎的一线治疗药物。然而，在反应中存在个体间和个体内的差异，其与活性多聚谷氨酸代谢物浓度的差异有关，而这些差异与临床疗效和毒性有关。在不同人群、疾病状态和方案中，处方仍然存在异质性。这篇综述检查了目前在类风湿关节炎背景下口服甲氨蝶呤的剂量反应知识，以及这如何帮助确定剂量方案。
相似文献
1
Optimising low-dose methotrexate for rheumatoid arthritis-A review.优化治疗类风湿关节炎的低剂量甲氨蝶呤：综述。
Br J Clin Pharmacol. 2019 Oct;85(10):2228-2234. doi: 10.1111/bcp.14057. Epub 2019 Aug 9.
2
Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.低剂量脉冲甲氨蝶呤在类风湿关节炎中的临床药代动力学
Clin Pharmacokinet. 1996 Mar;30(3):194-210. doi: 10.2165/00003088-199630030-00002.
3
Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.红细胞氨甲喋呤多聚谷氨酸的出现是类风湿关节炎中氨甲喋呤冲击治疗时剂量强度和给药途径的函数。
Rheumatology (Oxford). 2010 Dec;49(12):2337-45. doi: 10.1093/rheumatology/keq216. Epub 2010 Aug 16.
4
Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.接受长期甲氨蝶呤治疗的类风湿关节炎患者红细胞甲氨蝶呤多聚谷氨酸浓度的决定因素
Arthritis Rheum. 2009 Aug;60(8):2248-56. doi: 10.1002/art.24653.
5
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.头对头、随机、交叉研究口服与皮下给予甲氨蝶呤治疗类风湿关节炎患者：口服甲氨蝶呤剂量≥15mg 时药物暴露受限，通过皮下给予可能克服。
Ann Rheum Dis. 2014 Aug;73(8):1549-51. doi: 10.1136/annrheumdis-2014-205228. Epub 2014 Apr 12.
6
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.甲氨蝶呤剂量对早期类风湿关节炎患者的影响：甲氨蝶呤多聚谷氨酸药代动力学、阿达木单抗药代动力学和疗效：CONCERTO 试验的药代动力学和暴露-反应分析。
Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.
7
Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.在接受长期甲氨蝶呤治疗的类风湿关节炎患者中，甲氨蝶呤多聚谷氨酸盐浓度与疾病控制无关。
Arthritis Rheum. 2010 Feb;62(2):359-68. doi: 10.1002/art.27201.
8
High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients-A Preliminary Study.高甲氨蝶呤三谷氨酸水平是亚洲印度类风湿关节炎患者不良反应的独立预测指标——一项初步研究
Ther Drug Monit. 2017 Apr;39(2):157-163. doi: 10.1097/FTD.0000000000000375.
9
Benefit and risk of methotrexate treatment in rheumatoid arthritis.甲氨蝶呤治疗类风湿关节炎的益处与风险。
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S83-94.
10
Measuring methotrexate polyglutamates.测定甲氨蝶呤多聚谷氨酸。
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S24-6. Epub 2010 Oct 28.
引用本文的文献
1
A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report.一例成功使用司库奇尤单抗联合小剂量甲氨蝶呤治疗以确保持续清除的红皮病型银屑病病例报告
Case Rep Dermatol Med. 2025 May 29;2025:8810497. doi: 10.1155/crdm/8810497. eCollection 2025.
2
Differential response of tissue engineered skeletal muscle from rheumatoid arthritis patients and healthy controls.类风湿性关节炎患者与健康对照者的组织工程化骨骼肌的差异反应。
Commun Biol. 2025 Apr 9;8(1):583. doi: 10.1038/s42003-025-07970-8.
3
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.度维利塞是一种新型的NFAT抑制剂，可减轻阿达木单抗诱导的免疫原性。
Front Pharmacol. 2025 Jan 9;15:1397995. doi: 10.3389/fphar.2024.1397995. eCollection 2024.
4
Translational Research in Oral Lichen Planus: From Laboratory Discoveries to Clinical Applications.口腔扁平苔藓的转化研究：从实验室发现到临床应用
Cureus. 2024 Oct 14;16(10):e71462. doi: 10.7759/cureus.71462. eCollection 2024 Oct.
5
A reconfigurable integrated smart device for real-time monitoring and synergistic treatment of rheumatoid arthritis.一种用于类风湿性关节炎实时监测和协同治疗的可重构集成智能设备。
Sci Adv. 2024 May 3;10(18):eadj0604. doi: 10.1126/sciadv.adj0604. Epub 2024 May 1.
6
Effect of vitamin B12 on methotrexate-induced cardiotoxicity in rats.维生素B12对甲氨蝶呤诱导的大鼠心脏毒性的影响。
Iran J Basic Med Sci. 2024;27(6):733-739. doi: 10.22038/IJBMS.2024.74161.16120.
7
An acute herb-drug interaction of Magnoliae Officinalis Cortex with methotrexate via inhibiting multidrug resistance-associated protein 2.厚朴与甲氨蝶呤的急性药-药相互作用：通过抑制多药耐药相关蛋白 2。
J Food Drug Anal. 2024 Mar 15;32(1):103-111. doi: 10.38212/2224-6614.3495.
8
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes.类风湿关节炎的甲氨蝶呤治疗策略：关于剂量和给药途径的范围综述
BMC Rheumatol. 2024 Mar 5;8(1):11. doi: 10.1186/s41927-024-00381-y.
9
L-methionine protects against nephrotoxicity induced by methotrexate through modulation of redox status and inflammation.L-蛋氨酸通过调节氧化还原状态和炎症来预防甲氨蝶呤引起的肾毒性。
Redox Rep. 2023 Dec;28(1):2270886. doi: 10.1080/13510002.2023.2270886. Epub 2023 Nov 6.
10
Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature.口服与皮下注射甲氨蝶呤治疗免疫介导的炎症性疾病：当前文献更新。
Curr Rheumatol Rep. 2023 Dec;25(12):276-284. doi: 10.1007/s11926-023-01116-7. Epub 2023 Sep 28.
本文引用的文献
1
Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study.类风湿关节炎患者甲氨蝶呤转运体ABCG2的基因多态性、血压及动脉功能标志物：重复横断面研究
Pharmgenomics Pers Med. 2018 Nov 12;11:205-210. doi: 10.2147/PGPM.S170557. eCollection 2018.
2
Diagnosis and Management of Rheumatoid Arthritis: A Review.类风湿关节炎的诊断与治疗：综述。
JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103.
3
A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity.一例低剂量甲氨蝶呤中毒导致的快速死亡病例。
Case Rep Med. 2018 Jun 13;2018:9056086. doi: 10.1155/2018/9056086. eCollection 2018.
4
Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis.类风湿关节炎患者中低剂量甲氨蝶呤和 NSAIDs 联合使用与严重不良事件风险的关系。
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):885-893. doi: 10.1002/pds.4555. Epub 2018 May 24.
5
Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.炎性多关节炎患者口服甲氨蝶呤治疗失败的风险因素：一项英国前瞻性队列研究的结果。
Arthritis Res Ther. 2018 Mar 20;20(1):50. doi: 10.1186/s13075-018-1544-9.
6
Dissect new mechanistic insights for geniposide efficacy on the hepatoprotection using multiomics approach.采用多组学方法剖析京尼平苷对肝脏保护作用的新机制见解。
Oncotarget. 2017 Oct 19;8(65):108760-108770. doi: 10.18632/oncotarget.21897. eCollection 2017 Dec 12.
7
Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.在类风湿关节炎患者的单药治疗和联合治疗中，高剂量与低剂量甲氨蝶呤的短期临床疗效相似。
Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.
8
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.在日常实践中，与非最佳剂量相比，最佳甲氨蝶呤剂量与更好的临床结局相关：来自 ESPOIR 早期关节炎队列的结果。
Ann Rheum Dis. 2017 Dec;76(12):2054-2060. doi: 10.1136/annrheumdis-2017-211268. Epub 2017 Sep 2.
9
When less is more - efficacy with less toxicity at the ED50.少即是多——在半数有效剂量时疗效更佳且毒性更低。
Br J Clin Pharmacol. 2017 Jul;83(7):1365-1368. doi: 10.1111/bcp.13281. Epub 2017 Apr 6.
10
Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.类风湿关节炎患者甲氨蝶呤临床疗效的多态性和药物基因组学：系统评价和荟萃分析。
Sci Rep. 2017 Mar 7;7:44015. doi: 10.1038/srep44015.
Zotero 插件